INCY - Incyte Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Incyte Corporation

1801 Augustine Cut-Off
Wilmington, DE 19803
United States
302-498-6700
http://www.incyte.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees1,367

Key Executives

NameTitlePayExercisedYear Born
Mr. Hervé HoppenotChairman, Pres & CEO2.02MN/A1960
Ms. Maria E. PasqualeExec. VP & Gen. Counsel959.71kN/AN/A
Dr. Wenqing YaoExec. VP & Head of Discovery Chemistry687.16kN/A1963
Dr. Steven H. SteinExec. VP & Chief Medical Officer758.62kN/A1967
Ms. Christiana StamoulisExec. VP & CFON/AN/A1971
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc., as well as BriaCell Therapeutics Corp. for treating cancer. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Corporate Governance

Incyte Corporation’s ISS Governance QualityScore as of October 4, 2019 is 10. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.